Quarterly report pursuant to Section 13 or 15(d)

Commitments And Contingencies (Details)

Commitments And Contingencies (Details) $ / shares in Units, shares in Millions								1 Months Ended			3 Months Ended		12 Months Ended		16 Months Ended	39 Months Ended
	Apr. 01, 2021	Feb. 03, 2020 USD ($) milestone shares	Dec. 18, 2019 USD ($)	Aug. 08, 2019 USD ($)	Sep. 24, 2018 USD ($) therapy milestone shares	Feb. 16, 2018 unit $ / shares	Nov. 17, 2017 USD ($)	Dec. 31, 2019 USD ($)	Jul. 31, 2019 USD ($)	Aug. 31, 2017 USD ($)	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Apr. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Operating Leased Assets [Line Items]
Total revenue											$ 2,753,865	$ 2,576,369
Potential future regulatory milestone										$ 20,000,000
Payment received									$ 2,000,000
Period after public launch to terminate agreement									3 years
Percentage of net present value of royalty payments									75.00%
Aevi
Operating Leased Assets [Line Items]
Forgiveness of loan		$ 4,100,000						$ 4,100,000
Karbinal Agreement \| TRIS Pharma
Operating Leased Assets [Line Items]
Minimum quantity required \| unit						70,000
Make whole payment per unit (in dollars per share) \| $ / shares						$ 30
CERC-611
Operating Leased Assets [Line Items]
Potential milestone payment				$ 7,500,000
Potential milestone revenue threshold				750,000,000
Potential milestone payment two				12,500,000
Potential milestone revenue threshold two				1,300,000,000
License obligations				1,300,000
License and other revenue
Operating Leased Assets [Line Items]
Total revenue										$ 25,000,000
TRx
Operating Leased Assets [Line Items]
Potential milestone payment							$ 3,000,000
Milestone One \| TRx
Operating Leased Assets [Line Items]
Business combination gross profit														$ 12,600,000
Armistice \| CERC-611
Operating Leased Assets [Line Items]
Installment payment				$ 100,000
Total revenue													$ 100,000
Aevi
Operating Leased Assets [Line Items]
Unregistered shares of common stock issued or issuable as part of acquisition (in shares) \| shares		3.9
Contingent consideration		$ 6,500,000
Number of contingent consideration milestones \| milestone		2
Milestone payment		$ 0									0
Aevi \| Milestone One
Operating Leased Assets [Line Items]
Contingent consideration		2,000,000
Aevi \| Milestone Two
Operating Leased Assets [Line Items]
Contingent consideration		$ 4,500,000
Ichorion
Operating Leased Assets [Line Items]
Number of contingent consideration milestones \| milestone					3
Contingent consideration					$ 15,000,000
Milestone payment											$ 0
Issuance of shares in acquisition of Ichorion assets (in shares) \| shares					5.8
Ichorion \| CERC-801, CERC-802, And CERC-803
Operating Leased Assets [Line Items]
Number of preclinical therapies \| therapy					3
Ichorion \| CERC-913
Operating Leased Assets [Line Items]
Number of preclinical therapies \| therapy					1
Forecast \| Teva \| Millipred
Operating Leased Assets [Line Items]
Semi-annual license payment															$ 75,000
Renewal period	1 year
Forecast \| Ichorion \| Milestone One
Operating Leased Assets [Line Items]
Milestone payment																$ 6,000,000
Forecast \| Ichorion \| Milestone Two
Operating Leased Assets [Line Items]
Milestone payment																5,000,000
Forecast \| Ichorion \| Milestone Three
Operating Leased Assets [Line Items]
Milestone payment																$ 4,000,000
Contingent consideration \| Former TRx Owners
Operating Leased Assets [Line Items]
Damages sought			$ 3,000,000
Loss From Improper Treatment \| Former TRx Owners
Operating Leased Assets [Line Items]
Damages sought			9,200,000
Minimum \| Former TRx Owners
Operating Leased Assets [Line Items]
Estimate of possible loss			0
Maximum \| Former TRx Owners
Operating Leased Assets [Line Items]
Estimate of possible loss			$ 18,200,000